Journal Guide

Current Hematologic Malignancy Reports provides in-depth review articles contributed by international experts on the most significant developments in the field. By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the journal elucidates current and emerging approaches to the diagnosis, treatment, management, and prevention of conditions associated with hematologic malignancy.

Current Oncology Reports provides in-depth review articles contributed by international experts on the most significant developments in the field.  By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the journal serves all those involved in the diagnosis, treatment, management, and prevention of cancer.

Current Opinion in HIV and AIDS offers full and complete coverage enabling clinicians and researchers to keep up-to-date with the vast amount of information published in the field. Insightful editorials and on-the-mark invited reviews bring readers up-to-speed on key subjects such as the T-cell in HIV infection and disease, reservoirs, host factors, HIV vaccines, antiretroviral therapy and clinical trial design.Website: www.co-hivandaids.com.

Current Opinion in Oncology Online provides a powerful, broad-based perspective on the most important advances in the field from throughout the world literature. Reader-friendly, the journal features renowned guest editors focusing exclusively on two topics each issue. Bimonthly, every issue of Current Opinion in Oncology delivers unvarnished, expert assessments of developments from the previous year. Insightful editorials and on-the-mark invited reviews cover key subjects such as endocrine tumors; melanoma and other skin neoplasms; the genitourinary system; supportive care; cancer in AIDS; and the breast--some 18 or more items in all of major relevance. All reviews are supplemented with an indispensable section, 'References and Recommended Reading'. At the back of each volume is 'Current World Literature', an exceptionally thorough bibliography culled from the top 100 journals in the field.Website: www.co-oncology.com.

This reader-friendly, broad-based resource empowers those working in the fields of supportive and palliative care to put to good use vital clinical and research advances from throughout the world. The journal provides easy access to the very best thinking of the best minds in this dynamic, burgeoning field. Each quarterly issue features distinguished guest editors who focus exclusively on topics in their specialty. The journal delivers unvarnished, expert assessments of developments from the previous year8212;overviews found nowhere else. Insightful editorials and on-the-mark invited reviews bring readers up to speed on key subjects such as pain, gastrointestinal symptoms, psychological and cognitive problems, respiratory problems, renal and urological problems, bone and haematological problems, end-of-life management, cardiac and circulatory problems, cachexia, nutrition and hydration, HIV and other infections, quality of life, economics and ethics.All reviews are supplemented with an indispensable section, References and Recommended Reading. At the back of each volume is Current World Literature, an exceptionally thorough bibliography culled from the top 100 journals in the field. Website: www.co-supportiveandpalliativecare.com.

Each bimonthly issue of Current Problems in Cancer presents a single-topic, in-depth discussion, usually focused on the integrated management of a particular type of cancer or on a problem faced in a wide variety of malignancies. Issues may explore a particular category of drugs, an emerging interventional technique, or rehabilitation/reconstruction. Extensive bibliographies allow readers to easily locate additional information on related topics. Current Problems in Cancer serves the wide spectrum of physicians who treat patients with neoplastic disease.Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.If you require any further information or help, please visit our support pages: http://support.elsevier.com

Current Treatment Options in Oncology offers in-depth review articles contributed by international experts on the most significant developments in the field.  By providing clear, insightful, balanced review articles that emphasize recently published papers of major importance, the journal elucidates current and emerging approaches to the treatment of cancer.

‘Current Urology’ is an international peer-reviewed journal providing practical, timely, and state-of-the-art contributions on clinical research and experience in urology.

Cytotherapy is the Official Journal of the International Society for Cellular Therapy (ISCT).Cytotherapy publishes cutting edge findings, clinical trials of cell-based therapies, and news and opinion on all aspects of the rapidly expanding field of cell-based treatments for cancer, degenerative disorders, immunotherapy and stem cell transplantation. The journal focuses especially on the practical translation of scientific developments in the laboratory into clinical practice. Cytotherapy is an essential global resource for clinical researchers, oncologists, hematologists, physicians, and regulatory experts involved in cell processing and therapy.The journal's scope includes research in:Stem cell processing and transplantationCell-based therapies of malignant and non-malignant blood diseasesCancerStem cell plasticityAutoimmune diseasesImmunotherapyCongenital disordersNovel molecular therapiesGene therapyMicrovesicle biology and therapeutic application

Zielsetzung der Zeitschrift
Der Onkologe behandelt praxisnah Fragen zu Diagnose und Therapie onkologischer Er­krankungen. Besondere Berücksichtigung finden dabei die onkologisch arbeitenden Fachrichtungen Innere Medizin, Radiologie und Chirurgie. Die interdisziplinäre Zeitschrift richtet sich an onkologisch tätige Ärzte in Praxis und Klinik.
Umfassende Übersichtsarbeiten zu einem aktuellen Schwerpunktthema sind das Kernstück jeder Ausgabe. Im Mittelpunkt steht dabei evidenzbasiertes Wissen zu Diagnostik und Therapie mit hoher Relevanz für die tägliche Arbeit – der Leser erhält konkrete Handlungsempfehlungen. Die Schwerpunktthemen werden von einem unabhängigen Herausgeberboard geplant. Ausgewiesene Experten verfassen anschließend die aufeinander abgestimmten Beiträge.
Beiträge der Rubrik „CME Zertifizierte Fortbildung“ bieten gesicherte Ergebnisse wissenschaftlicher Forschung und machen ärztliche Erfahrung für die tägliche Praxis nutzbar. Nach Lektüre der Beiträge kann der

Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.

Drug Resistance Updates is a bimonthly publication that contains thought-provoking reviews on important developments in drug resistance in infectious disease and cancer as well as novel drugs and strategies to overcome drug resistance.It covers both basic research and clinical aspects of drug resistance, and involves disciplines as diverse as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology and clinical medicine.Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective.*Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research

Endocrine-Related Cancer is the established global journal for basic, translational and clinical research on hormones and cancer. Endocrine-related cancers typically include cancers of the breast, prostate, pituitary, testes, ovary and neuroendocrine system as well as hormone-dependent cancers elsewhere.

The European Journal of Cancer (EJC) is an international multidisciplinary oncology journal, which publishes original research, reviews, and editorial comments on basic and preclinical cancer research, translational oncology, clinical oncology - including medical oncology, paediatric oncology, radiation oncology, and surgical oncology, and cancer epidemiology and prevention.The EJC is the official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO), the European Association for Cancer Research (EACR) and the European Society of Breast Cancer Specialists (EUSOMA).Why publish your work in the EJC?Efficient peer-review: The EJC's Editors and reviewers are committed to maintaining the high standards of the journal. All manuscripts submitted to the EJC will be evaluated by the journal's Editors. Some manuscripts may be rejected outright following this evaluation, allowing the authors to submit their work elsewhere. Those manuscripts which are judged as being eligible for consideration by the Editors will be subject to peer-review. The full peer-review policy for the EJC can be found here.The EJC has an online submission and peer-review system to facilitate the submission and peer-review of submitted manuscripts. Authors are able to upload their manuscript quickly and track the status of their manuscript throughout the review process.Online Publication as an Article-in-Press: All manuscripts that are accepted for publication in the EJC are published online as Articles-in-Press within 4 - 5 weeks of acceptance. Articles-in-Press can be cited using the unique digital object identifier (DOI) which is assigned to all papers. In addition, Articles-in-Press are indexed in PubMed.The EJC's readership: The EJC is published in print and online and is available to more than 17,000 academic and clinical institutions, personal subscribers and members of the journal's Society Partners (the EORTC, ECCO, EACR and EUSOMA). In 2011 the journal had more than 83,000 articles downloaded per month from across the world.The EJC has an iPad app, making each issue of the journal available to our readers in this format. Visit http://itunes.apple.com/us/app/ejc-app/id461022524?mt=8 to find out more.eTables of Contents: Our readers can elect to receive free eTables of Contents via email, which are sent out for each issue of the journal.Abstracting and Indexing Coverage: The EJC is included in the leading abstracting and indexing services, including PubMed/MEDLINE, Current Contents/Clinical Medicine, the Science Citation Index, the Journal Citation Reports and Scopus.HINARI: The EJC is part of HINARI (Health InterNetwork Access to Research Initiative) administered by the World Health Organisation. The HINARI Programme enables developing countries to gain access to one of the world's largest collections of biomedical and health literature.Why read the EJC?High quality original research and review articles: The EJC is a multidisciplinary journal, publishing high quality original research and review articles on basic and preclinical research, translational oncology, clinical oncology (medical, paediatric, radiation, surgical), and cancer epidemiology and prevention from across the world.Guidelines: The EJC is privileged to publish selected treatment guidelines from the journal's Society Partners (the EORTC, ECCO, EACR and EUSOMA) and other groups.Special Series: The EJC publishes special series of papers on linked topics of particular relevance and interest to the journal's readers.EJC News and EJC News Focus: Each month, the journal publishes the EJC News, discussing and commenting on current issues in cancer, together with the EJC News Focus, a series of video interviews with key opinion leaders in oncology.

The European Journal of Cancer Care aims to encourage comprehensive, multiprofessional cancer care across Europe and internationally. It publishes original research reports, literature reviews, guest editorials, letters to the Editor and special features on current issues affecting the care of cancer patients. The Editor welcomes contributions which result from team working or collaboration between different health and social care providers, service users, patient groups and the voluntary sector in the areas of: Primary, secondary and tertiary care for cancer patients Multidisciplinary and service-user involvement in cancer care Rehabilitation, supportive, palliative and end of life care for cancer patients Policy, service development and healthcare evaluation in cancer care Psychosocial interventions for patients and family members International perspectives on cancer care The journal provides a forum for multiprofessional and service-user dialogue, and the reporting of original research or rigorous reviews within the field of cancer care both in Europe and internationally. The journal welcomes original research, reviews and correspondence from individuals whose first language is not English, but places great weight in its published papers on accuracy, fluency and clarity of expression as befits any journal published for an international and multiprofessional audience.

The European Journal of Cancer Prevention emphasizes the rapid publication of important research into fundamental aspects of cancer prevention, making it essential reading for researchers in a wide variety of fields. The scope is wide ranging, including descriptive and metabolic epidemiology, histopathology, lifestyle issues, environment, genetics, biochemistry, molecular biology, microbiology, clinical medicine, intervention trials and public education, basic laboratory studies and special group studies.Website: www.eurjcancerprev.com.

EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal's websites.EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention.Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief.EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European Association for Cancer Research (EACR), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).